The Hyalofast PMA rejection is a material pipeline setback that may weigh on the stock despite solid operational results and raised guidance. Watch for management's next steps on Hyalofast regulatory pathway and any update on Cingal NDA timeline.
Drugs in focus
ANIK drug pipeline →CINGAL
● Neutral Named in this 8-K- Impact
- Phase
- Pre-NDA (US drug application path; not a standard clinical phase)
- Time to market
- Unknown, and likely 2027 at the earliest: the NDA had not been confirmed as filed as of mid-2026, and a US approval decision would typically come roughly 10 months after a completed, accepted submission.
- Next catalyst
- None dated
What to watchWatch Anika's Q3 2026 earnings call (next scheduled update) for a confirmation that the Cingal NDA was formally submitted and for FDA acceptance, that would finally give the stock a dated regulatory clock. Until a submission is confirmed, treat Cingal as a 2027+ US revenue story, not a near-term binary; near-term price action is being driven by the Q2 2026 earnings beat and guidance raise rather than by Cingal news.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $14.55entry
- T+1 · 8d ago +0.14%α −2.23% · $14.57
- T+5 · 4d ago −7.90%α −10.50% · $13.40
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Anika Therapeutics reported Q3 2026 revenue of $30.6M (+10% YoY), slightly above the $29.4M consensus, with Commercial Channel revenue up 17% and OEM up 5%. GAAP EPS was -$0.02, while adjusted EPS was $0.29, above the $0.17 consensus. The company raised the lower end of full-year 2026 revenue guidance (6%-10% growth) and raised adjusted EBITDA margin guidance to 15%-17%. However, the FDA issued a 'not approvable' letter for the Hyalofast PMA, a key pipeline asset, offsetting the positive operational momentum.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $30.6M, up 10% YoY from $27.8M
- Commercial Channel revenue $14.0M, up 17% YoY
- OEM Channel revenue $16.6M, up 5% YoY
- GAAP loss from continuing operations $0.3M, or $0.02 per diluted share
- Adjusted net income from continuing operations $3.9M, or $0.29 per diluted share
- Adjusted EBITDA $5.1M
- Gross margin 62%, up from 56% in prior-year period
- Full-year 2026 total company revenue guidance raised to 6%-10% growth (from 5%-10%)
- Full-year 2026 adjusted EBITDA margin guidance raised to 15%-17% (from 13%-17%)
- FDA issued 'not approvable' letter for Hyalofast PMA in October 2026
- Cingal bioequivalence study enrollment completed; NDA submission expected before year-end 2027
- New 10-year Hyvisc partnership with Boehringer Ingelheim; expects $8M in payments including $4M upfront in Q1 2027
- Integrity revenue grew more than 30% YoY and contributed $7.5M in trailing 12 months
- Cash and cash equivalents $45.0M as of September 30, 2026
Financial Impact
Revenue beat consensus by ~$1.2M (4.1%); adjusted EPS of $0.29 beat consensus of $0.17 by 70.6%. Hyalofast setback removes a key pipeline catalyst with uncertain regulatory path.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| OEM Channel | $16.6M | +5.0% |
| Commercial Channel | $14.0M | +17.0% |
Risk Factors
- Hyalofast PMA not approvable by FDA; future regulatory path uncertain
- Commercial Channel revenue guidance lowered to 9%-13% from 12%-18% due to slower elective surgery market
- GAAP net loss of $0.3M in the quarter
- Cash burn from operations and investing activities; cash declined to $45.0M from $57.5M at year-end 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-007211 |
| Document: f8k_110626.htm | 0001171843-26-007211 |
| Document: 0001171843-26-007211-index-headers.html | 0001171843-26-007211 |
| Document: 0001171843-26-007211-index.html | 0001171843-26-007211 |
| Document: 0001171843-26-007211.txt | 0001171843-26-007211 |
| 8-K Data (Synthetic) | 0001171843-26-007211 |
Track record
13 reports on ANIK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 8-K Mixed 6/10 Viewing Entry $14.55 Now $12.92 −11.20% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
- Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
- Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
- Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
- Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
- Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers